



"Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast **Cancer Patients with Positive Nodes using low-cost dual dye technique:** Identifying factors associated with adequate FNR threshold"

The World's Congress of Surgery

Animesh, Jayesh Chavda, Arpan Mishra, Ashutosh Silodiya, Sanjay Kumar Yadav, Deepti Bala Sharma, Dhananjaya Sharma, Muktesh Khandare

Netaji Subhash Chandra Bose Medical College, Jabalpur, Madhya Pradesh, India

INTRODUCTION

- •SLNB with radio-pharmaceutical and blue dye is recommended for early breast cancer with cN0 axilla
- Higher FNR limits routine SLNB use in LABC with cN1-3 axilla rendered node negative after NACT(ycN0)
- •Critical for global south, where most patients present with LABC and receive NACT
- •This study evaluated feasibility of FG(fluorescein guided) SLNB with MBD(methylene blue dye) for SLN identification and factors to achieve 10% **FNR threshold**

RESULTS

Table 1: SLN-IR using dyes and their combination

	Post neoadjuvant chemotherapy cN0 patients				
	Identification of SLN (no. of patients)	SLN identification rate (%)			
MBD	102	85.0			
FD	99	82.5			
MBD+FD	102	85.0			

Table 2: SLN false negative rate

MATERIALS AND METHODS		Post neoadjuvant chemotherapy cN0 patients			
 prospective cross-sectional validation study Validation of SLNB using fluorescein and MBD, followed by ALND regardless of SLNB histology 		(n)	FN-SLN (number of patients)	ТР	Percentage FNR = (FN/ FN +TP) X 100 (%)
•SLN-IR and FNR were assessed and	Overall	102	11	52	17.4%
compared across molecular subtypes	1 SLN	30	7	21	25%
SAMARTH	2 or > 2 SLN	72	4	31	11.42%
Methylene Blue Injection USP	Luminal A+B with 1 SLN	16	4	11	26.7%
10 mg/ml For IV Use 5 X 10 ml	HER 2 enriched with 1 SLN	6	1	4	20%
	TNBC with 1 SLN	8	2	6	25%
	Luminal A+B with 2 SLN	35	3	18	11.11%
FLUORESCEIN INJECTION USP FLURESIN [™]	HER 2+ with 2 SLN	13	1	12	7.7%
10% For Diagnostic Fluorescein Angiography or Angioscopy For LV. use only	TNBC with 2 SLN	24	0	1	0%

DISCUSSION & CONCLUSION

- Dual tracers in SENATINA/ACOSOG achieved SLN IR of 87.8-92.9% v/s MBD+FS dye shows SLN IR of 85% (our study)
- FNR of 17.4% is comparable to ACOSOG Z107 and SNFNAC trails
- Fibrosis after NACT may affect lymphatic drainage and reduce SLN identification
- Feasible in low resource setting
- •SLN mapping with low-cost dual dyes(MBD+FS) is feasible, but FNR is too high
- Improved with more SLNs excised and in Her2-enriched/TNBC profiles

References



1.Mocellin, S., Goldin, E., Marchet, A., & Nitti, D. (2015). Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and metaanalysis. International Journal of Cancer, 138(2), 472-480. https://doi.org/10.1002/ijc.29644

2.Chavda, J., Mishra, A., Silodia, A., Yadav, S. K., Sharma, D. B., Sharma, D., & Khandare, M. (2022b). Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings. Breast Cancer Research and Treatment, 193(1), 105-110. https://doi.org/10.1007/s10549-022-06556-w